Hematology

Patients treated with liso-cel had a probability of continued response at 2-years of 49.5%.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH study of fitusiran.

Poseida’s announcement follows their presentation of positive data in metastatic castrate-resistant prostate cancer in September 2021.

The program is still on clinical hold following SUSARs of myelodysplastic syndrome in treated participants.

The FDA has placed a partial clinical hold on the program for patients that are under the age of 18 after an adolescent patient developed persistent anemia.

The professor from The University of Texas MD Anderson Cancer Center discussed long-term follow-up analysis of the phase 2 ZUMA-5 trial.

PET/CT plays a central role in evaluating response after CAR T-cell therapy.

Review top news and interview highlights from the week ending December 17, 2021.

Safety and the recommended dose of CYAD-211 and the lymphodepletion regimen served as the primary end point of the study.

Patients treated with cilta-cel had a 76% reduction in the risk of death compared to patients treated with physician's choice of treatment.

The vice chair, Blood and Marrow Transplant and Cellular Immunotherapy Program, and co-leader, Immuno-Oncology, Moffitt Cancer Center, discussed the results of the phase 3 ZUMA-7 trial.

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed safety findings from the phase 3 ALLELE study.

Annualized bleeding rate, spontaneous bleeding, and joint bleeding rates were all reduced in patients dosed with fitusiran compared to those receiving on-demand treatment.

Over half of patients in the fitusiran arm of the ATLAS-INH study had 0 treated bleeding events.

The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.

The findings, which were simultaneously reported in the New England Journal of Medicine, support beti-cel as a potentially curative, one-time treatment option for these patients.

ADI-001 does not require genetic engineering to remove TCRs to avoid GvHD, making them ideal for an off-the-shelf cell therapy.

The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.

The hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Patients treated with the CAR T-cell therapy had an over 4-fold increase in event-free survival.

Review top news and interview highlights from the week ending December 9, 2021.

All evaluable treated participants experienced a reduction in vaso-occlusive events after treatment with ARU-1801.

CSL Behring plans to submit regulatory applications in the US and EU in the first half of 2022 for the AAV gene therapy etranacogene dezaparvovec.

The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.

Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.